Valencia-based efficacy testing laboratory Dermaclaim Lab completed its most ambitious international tradeshow season to date in H1 2026 — and the conversations it had across four continents signal where global claim substantiation standards are heading next.
Dermaclaim Lab S.L., the Valencia-based dermocosmetic testing laboratory founded in October 2021, wrapped up its most expansive international trade fair presence to date in the first half of 2026. The laboratory — which specialises in efficacy claim substantiation for finished cosmetic products and active ingredients — exhibited at four major industry events across three continents: PCHi China in Hangzhou, in-cosmetics Global in Paris, Vitafoods Europe in Barcelona, and NYSCC Suppliers' Day in New York.
For Indian cosmetic brands, manufacturers, and R&D teams, this is more than a company announcement. It signals the accelerating globalisation of rigorous, science-backed claims infrastructure — and positions Dermaclaim Lab as an accessible international partner for Indian brands navigating increasingly evidence-hungry markets.
Each event on Dermaclaim's circuit carries a distinct relevance for the Indian BPC industry.
PCHi China — one of Asia's most influential personal care and home ingredients events — is where Dermaclaim engaged regional manufacturers seeking regulation-aligned claim substantiation for Asian markets. Indian brands exporting to or sourcing from the ASEAN and East Asian supply chain should note that claims scrutiny in these markets is rising, and testing documentation produced by accredited European laboratories carries weight.
In-cosmetics Global in Paris remains the world's pre-eminent forum for cosmetic ingredient innovation. Dermaclaim's stand reportedly drew consistent interest in in vitro, ex vivo, and clinical testing partnerships — reflecting a broader market appetite for substantiation that goes beyond basic stability data. For Indian brands formulating with active ingredients and positioning on functional claims, this is the standard that export buyers are now expecting.
Vitafoods Europe highlighted Dermaclaim's expansion into bioassay-based substantiation for active ingredient suppliers operating at the cosmetic-nutraceutical interface. This is directly relevant for Indian nutraceutical and Ayurvedic brands making skin, hair, or nail efficacy claims on beauty-adjacent products.
NYSCC Suppliers' Day in New York addressed the North American supply chain's demand for internationally recognised scientific documentation. Indian CMOs and ingredient exporters with ambitions in the US market should understand that unsubstantiated claims are a material regulatory risk under the FTC Act and state-level consumer protection frameworks.
Dermaclaim's conversations across all four events spanned the full range of its methodology stack — a useful reference point for Indian R&D professionals evaluating their own claims documentation:
The range is significant. Many Indian brands rely on supplier-provided in vitro data to support claims on finished products — a practice that carries risk if the data was generated on an ingredient in isolation rather than in the finished formulation. Dermaclaim's model, testing at both ingredient and finished product level, reflects where the global standard is moving.
CEO and Founder David González Fernández noted that the four-show circuit confirmed a clear market reality: demand for rigorous, science-first claim substantiation is growing globally, and the laboratory is positioned to serve it. Dermaclaim reported 26% revenue growth in 2025 and has recently consolidated its laboratory and clinical departments into a single integrated facility — operational signals that suggest a business scaling to meet sustained demand.
India's regulatory framework for cosmetic claims sits under the Drugs and Cosmetics Act, 1940, with CDSCO guidance and Bureau of Indian Standards specifications providing the operative compliance layer. The ASCI (Advertising Standards Council of India) and the Legal Metrology Act add a consumer-facing claims accountability dimension.
Enforcement has historically been uneven, but this is changing. CDSCO has progressively tightened post-market surveillance, and brand-level claims — particularly those touching therapeutic-adjacent language like "repairs", "regrows", or "clinically proven" — are attracting closer scrutiny. For brands with export ambitions, EU Regulation (EC) No 1223/2009 and the US FTC framework impose substantially higher evidentiary standards.
The gap between what Indian brands claim and what they can substantiate with credible scientific documentation remains wide. This gap is both a compliance risk and a competitive disadvantage in export conversations.
The practical opportunity from Dermaclaim's expanded international presence is straightforward: Indian brands now have a clearer pathway to access internationally accredited, Europe-based efficacy testing without navigating opaque procurement relationships.
For active ingredient suppliers — particularly those producing plant extracts, Ayurvedic actives, or fermentation-derived ingredients for cosmetic application — commissioning in vitro bioassay studies through a laboratory like Dermaclaim provides export-ready data packages that hold up in EU and US regulatory conversations. This is a one-time investment per ingredient that can underpin multiple finished product launches.
For finished product brands targeting premium domestic positioning or export markets, clinical trial data on the specific formulation — not borrowed from ingredient supplier dossiers — is the credible evidentiary standard. A hydration or firmness claim backed by a 30-subject, instrument-measured clinical study is materially stronger than a claim referenced from a supplier's in vitro sheet.
For contract manufacturers building out their service capability, the ability to offer clients a testing and claim substantiation pathway — even through a third-party laboratory relationship — is a tangible differentiator in a market where brand clients are increasingly asking "can you help us prove this claim?"
Dermaclaim has confirmed that the next four tradeshows on its calendar fall between September and November 2026. Indian brands attending in-cosmetics India or global events in that window should treat this as a direct opportunity for face-to-face engagement with a laboratory that is actively building its Asian client base.
The global claim substantiation standard is not waiting for the Indian market to catch up. The brands that close this gap proactively will be better placed — both in domestic regulatory conversations and in the international brand-building that India's BPC sector is increasingly pursuing.
With 40 million monthly active users searching for specific notes, accords, and ingredients, Fragrantica is one of the most underutilised demand intelligence tools available to Indian fragrance procurement and formulation teams.
China's perfume clubs are turning scent into a social ritual. Here's why experiential discovery is the next strategic battleground for India's fast-growing fragrance brands.
